|
Phase 2 study of ET-743 in persistent or recurrent endometrial carcinoma Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Phase 2 study of ET-743 in persistent or recurrent endometrial carcinoma conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Phase 2 study of ET-743 in persistent or recurrent endometrial carcinoma Clinical research trials and Phase 2 study of ET-743 in persistent or recurrent endometrial carcinoma medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Phase 2 study of ET-743 in persistent or recurrent endometrial carcinoma. Phase 2 study of ET-743 in persistent or recurrent endometrial carcinoma Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Phase 2 study of ET-743 in persistent or recurrent endometrial carcinoma clinical trial. Subjects typically recieve the finest healthcare available for their Phase 2 study of ET-743 in persistent or recurrent endometrial carcinoma condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase 2 study of ET-743 in persistent or recurrent endometrial carcinoma  Phase 2 study of ET-743 in persistent or recurrent endometrial carcinoma
Phase 2 study of ET-743 in persistent or recurrent endometrial carcinoma
For Condition: Endometrial Neoplasms
Status: Recruiting
Sponsor(s): Johnson & Johnson Pharmaceutical Research and Development, L.L.C. , PharmaMar
Synopsis: This is a study is to test the safety and effectiveness of an investigational chemotherapy agent in subjects with persistent or recurrent endometrial cancer. After a subject meets all entry criteria and signs informed consent she will be enrolled in the study. Participants will be required to attend regular clinic visits to receive study medication and have their status monitored. They will also be required to have radiologic tumor assessments performed at multiple times throughout the study. A detailed explanation can be provided by the investigator conducting this study.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: - Female subjects 18 years of age or older - Diagnosis of advanced or metastatic endometrial carcinoma - Progressive disease after 1 cytotoxic chemotherapy regimen given for advanced/metastatic disease - At least one measureable tumor lesion - Adequate bone marrow, hepatic and renal function - Performance status ECOG 0 or 1
Total Enrollment:
Location and Contact Information:
Ochsner Cancer Institute *Recruiting*
New Orleans, Louisiana, 70121
United States
Recruiting Carol Marques 504-842-3708
University of Medicine & Dentistry of NJ *Not yet recruiting*
Newark, New Jersey,
United States
Not yet recruiting Tracie SAunders 973-972-7789
Hematology Oncology P.C. *Recruiting*
Stamford, Connecticut, 06902
United States
Recruiting Susan Murdock 203-323-8944
NYU School of Medicine *Recruiting*
New York City, New York, 10016
United States
Recruiting Clinical Office 212-263-6485
US Oncology, Dallas *No longer recruiting*
Dallas, Texas, 75204
United States
No longer recruiting
USC, Norris Comprehensive Cancer Center *Recruiting*
Los Angeles, California, 90089
United States
Recruiting Susan Edwards 323-865-0455
Cleveland Clinic Foundation, Taussig Cancer Center *Not yet recruiting*
Cleveland, Ohio, 44195
United States
Not yet recruiting Melinda Sessanna 216-444-3414
Northon Hospitals, Inc., Louisville Oncology *Recruiting*
Louisville, Kentucky, 40202
United States
Recruiting Daniella Neamtu 502-629-4679
University of Oklahoma Health Science Center *Recruiting*
Oklahoma City, Oklahoma, 73104
United States
Recruiting Ingrid Block 405-271-8777
Vanderbilt-Ingram Cancer Center *Recruiting*
Nashville, Tennessee, 37232
United States
Recruiting Sheryl Redlin-Frazier 615-322-2114
MUSC, Hollings Cancer Center *Recruiting*
Charleston, South Carolina, 29425
United States
Recruiting Pam Strange 843-792-6394
University of Miami, Sylvester Comprehensive Cancer Center *Not yet recruiting*
Miami, Florida, 33136
United States
Not yet recruiting Franchette Auguste 305-243-1260
Franklin Square Hospital Center *Recruiting*
Baltimore, Maryland, 21237
United States
Recruiting Karen Oleszewski 443-777-7136
University of Kentucky, Chandler Medical Center *Recruiting*
Lexington, Kentucky, 40536
United States
Recruiting Michelle Hughes 859-257-4944
Hematology Oncology Specialists *Recruiting*
New Orleans, Louisiana, 70115
United States
Recruiting Mary Ostroske 504-894-7115
Additional Information:
Study ID Numbers: ET743-USA-1;
Study Start Date:
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00050440
Other Endometrial Neoplasms Studies:
1. Phase 2 study of ET-743 in persistent or recurrent endometrial carcinoma
Related Studies:
Other Endometrial Neoplasms Clinical Trials
Other Oklahoma Clinical Trials
Other Oklahoma City Clinical Trials
Phase 2 study of ET-743 in persistent or recurrent endometrial carcinoma
|
|
|
|
|
|
|
|
